OTCPK:CANL

Stock Analysis Report

Executive Summary

CannLabs, Inc. provides cannabis testing laboratory services in the United States.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • CannLabs has significant price volatility in the past 3 months.
  • CannLabs's last earnings update was 1533 days ago.
  • CannLabs is not covered by any analysts.

Similar Companies

Share Price & News

How has CannLabs's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.1%

OTCPK:CANL

0.1%

US Healthcare

0.8%

US Market


1 Year Return

-44.9%

OTCPK:CANL

-8.4%

US Healthcare

1.9%

US Market

CANL underperformed the Healthcare industry which returned -7.7% over the past year.

CANL underperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

CANLIndustryMarket
7 Day0.1%0.1%0.8%
30 Day-0.2%-1.4%3.4%
90 Day-17.9%-0.7%2.1%
1 Year-44.9%-44.9%-7.0%-8.4%4.2%1.9%
3 Year-55.1%-55.1%30.6%25.3%46.7%37.2%
5 Year-91.3%-91.3%64.9%55.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is CannLabs's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CannLabs undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether CannLabs is trading at an attractive price based on the cash flow it is expected to produce in the future. But as CannLabs has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine CannLabs's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through CannLabs regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is CannLabs expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CannLabs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has CannLabs performed over the past 5 years?

0.1%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, CannLabs has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is CannLabs's financial position?


In this section we usually analyse CannLabs's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. CannLabs has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of CANL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when CannLabs's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is CannLabs's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate CannLabs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate CannLabs's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as CannLabs has not reported any payouts.

Unable to verify if CannLabs's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as CannLabs has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of CannLabs's salary, the management and board of directors tenure and is there insider trading?

5.3yrs

Average board tenure


CEO

Mark Mirken (74yo)

4.1yrs

Tenure

US$6,091,115

Compensation

Mr. Mark C. Mirken has been the Chairman and Chief Executive Officer of Cannlabs, Inc. since August 7, 2015. Mr. Mirken served as the Chairman and Chief Executive Officer at Inergetics, Inc., (formerly Mil ...


CEO Compensation Analysis

Insufficient data for Mark to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.

Insufficient data for Mark to compare compensation growth.


Board Age and Tenure

5.3yrs

Average Tenure

63yo

Average Age

The tenure for the CannLabs board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Mark Mirken (74yo)

    Chairman & CEO

    • Tenure: 4.1yrs
    • Compensation: US$6.09m
  • Michael Wempe

    Head of Consulting and Research Department

    • Tenure: 0yrs

Board Members

  • Carl Banzhof (51yo)

    Member of Business and Technology Advisory Board

    • Tenure: 5.3yrs
  • Jon Merriman (59yo)

    Member of Business and Technology Advisory Board

    • Tenure: 5.3yrs
  • Mark Mirken (74yo)

    Chairman & CEO

    • Tenure: 4.1yrs
    • Compensation: US$6.09m
  • Joe Albaugh (67yo)

    Director

    • Tenure: 5.7yrs
  • Margaret Gedde

    Member of Science Advisory Board

    • Tenure: 0yrs
  • Paul Matthews

    Member of Science Advisory Board

    • Tenure: 0yrs

Company Information

CannLabs, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CannLabs, Inc.
  • Ticker: CANL
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$5.631m
  • Shares outstanding: 62.63m
  • Website: https://null

Number of Employees


Location

  • CannLabs, Inc.
  • 3888 East Mexico Avenue
  • Suite 202
  • Denver
  • Colorado
  • 80210
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CANLOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJun 2014

Biography

CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 01:14
End of Day Share Price2019/09/17 00:00
Earnings2015/03/31
Annual Earnings2014/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.